Skip to Content

Infinity Pharmaceuticals Inc INFIQ

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

INFIQ is trading at a 75% premium.
Price
$0.00
Fair Value
$1.79
Uncertainty
Extreme
1-Star Price
$2.18
5-Star Price
$7.72
Economic Moat
Qphc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INFIQ is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.24
Bid/Ask
$0.00 / $0.00
Market Cap
$90.76
Volume/Avg
1,840 / 5,269

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Infinity Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology related treatments. The company operates in only one segment which is drug development.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
30

Valuation

Metric
INFIQ
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
INFIQ

Financial Strength

Metric
INFIQ
Quick Ratio
1.47
Current Ratio
1.65
Interest Coverage
−226.49
Quick Ratio
INFIQ

Profitability

Metric
INFIQ
Return on Assets (Normalized)
−87.96%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
INFIQ
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
BljzfvdkbhGmpwb$636.2 Bil
Vertex Pharmaceuticals Inc
VRTX
MscfprmbfGldnstj$126.1 Bil
Regeneron Pharmaceuticals Inc
REGN
PrpjggsJljzx$121.2 Bil
Moderna Inc
MRNA
RqdqyphdVnfy$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
HrrymfxszRtmgsn$33.0 Bil
argenx SE ADR
ARGX
WrfgxjdfYnzgz$27.9 Bil
BioNTech SE ADR
BNTX
SyjsbkygPjsmy$20.5 Bil
Biomarin Pharmaceutical Inc
BMRN
DkfbngwblJpmbbvm$16.1 Bil
United Therapeutics Corp
UTHR
DmbrklgpHzxt$14.3 Bil
Incyte Corp
INCY
VclkblbhQxpdly$12.5 Bil

Sponsor Center